Literature DB >> 7773165

The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes.

J F Seymour1, E H Estey.   

Abstract

Auer rods were first recognized at the beginning of this century. Their presence soon became considered to be an unequivocal manifestation of a leukemic process. Possibly influenced by this long-held assumption, in 1982 the French-American-British co-operative group (FAB) incorporated the presence of Auer rods into a classification system of the myelodysplastic syndromes that remains in widespread clinical usage today. Although unsubstantiated at the time, the presence of Auer rods was suggested to indicate a rapidly progressive disorder and a poor prognosis. In the absence of studies confirming the utility of Auer rods as a diagnostic criterion, the FAB classification system of myelodysplastic syndromes has been widely used to allocate therapy. In this review we examine the early descriptions of Auer rods and critically evaluate the studies examining the value their presence has in the classification and prognosis of patients with myelodysplastic syndromes.

Entities:  

Mesh:

Year:  1995        PMID: 7773165     DOI: 10.3109/10428199509051706

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

Authors:  Luca Maurillo; Francesco Buccisano; Maria Ilaria Del Principe; Chiara Sarlo; Luigi Di Caprio; Concetta Ditto; Federica Giannotti; Daniela Nasso; Eleonora Ceresoli; Massimiliano Postorino; Marco Refrigeri; Sergio Amadori; Adriano Venditti
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-06-03       Impact factor: 2.576

2.  Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia.

Authors:  Huijun Huang; Tiejun Qin; Zefeng Xu; Zhongxun Shi; Bing Li; Lijuan Pan; Naibo Hu; Shiqiang Qu; Gang Huang; Robert P Gale; Zhijian Xiao
Journal:  Br J Haematol       Date:  2019-12-27       Impact factor: 8.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.